Adaptimmune Therapeutics Plc ADR’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $2.05 on 03/08/24 and a low of $0.42 for the same time frame on 11/28/23.
52-week price history of ADAP Stock
Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Adaptimmune Therapeutics Plc ADR’s current trading price is -36.83% away from its 52-week high, while its distance from the 52-week low is 208.33%. The stock’s price range during the 52-week period has remained between $0.42 and $2.05. In the Healthcare sector, the company’s shares saw a trading volume of around 1.08 million for the day, which was evidently lower than the average daily volume of 1.62 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Adaptimmune Therapeutics Plc ADR (ADAP) has experienced a quarterly rise of 19.91% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 330.87M and boasts a workforce of 449 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.1946, with a change in price of -0.2800. Similarly, Adaptimmune Therapeutics Plc ADR recorded 1,646,759 in trading volume during the last 100 days, posting a change of -17.61%.
Examining ADAP’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ADAP stands at 0.97. Similarly, the long-term debt-to-equity ratio is also 0.76.
ADAP Stock Stochastic Average
As of today, Adaptimmune Therapeutics Plc ADR’s raw stochastic average for the last 50 days stands at 88.99%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 88.89%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 79.17% and 73.89%, respectively.
ADAP Stock Price Performance Analysis
The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The metric has seen a significant gain of 63.30% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 81.12%. Over the past 30 days, the price of ADAP has fallen by 49.56%. And in the last five days, it has surged by 9.75%.
